Collecting duct carcinoma of the kidney: the decisions you may face

Cancer page →Second-opinion finder →

1 treatment setting, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

All stages

2 optionsCompare side by side →

Nephrectomy where resectable; gemcitabine with cisplatin or carboplatin for metastatic disease, borrowed from urothelial cancer; renal cell carcinoma drugs have little evidence here.

The options, in plain words

Gemcitabine + cisplatinStandard of careCytotoxic regimen

Gemcitabine plus cisplatin has been the chemotherapy backbone for bile duct cancer since 2010 and is now given with immunotherapy.

CarboplatinApprovedCytotoxic chemotherapy (platinum)

Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.

Also referenced:NephrectomyRenal cell carcinoma

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Gemcitabine + cisplatin all recorded rates →

Side effect	Any grade	Grade 3+
Neutropenia (grade 3-4) · TOPAZ-1, placebo plus gemcitabine-cisplatin arm, laboratory values (durvalumab US label); the ABC-02 figures could not be checked against the paper	-	49%
Fatigue · TOPAZ-1, placebo plus gemcitabine-cisplatin arm (n=342), durvalumab US label	43%	6%

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Carboplatin all recorded rates →

Dose by Calvert formula using GFR (see the calculators).

Questions to ask about this decision

Between Gemcitabine + cisplatin and Carboplatin, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
Which side effects of Gemcitabine + cisplatin are most likely for me, which are reversible, and which would make us stop?
Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (all stages), which of the standard options do you recommend and why?
Why: Guideline options include: Nephrectomy where resectable; gemcitabine with cisplatin or carboplatin for metastatic disease, borrowed from urothelial cancer; renal cell carcinoma drugs have little evidence here.
Am I a candidate for Gemcitabine + cisplatin, Carboplatin, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care